1 for phase i component of the study patient with refractory or relapse acute myelogenous leukemia aml acute lymphocytic leukemia all and myelodysplastic syndrome md be eligible patient with chronic lymphocytic leukemia cll be eligible if fludarabine base therapy have fail patient with chronic myeloid leukemia cml be eligible if they have document hematologic resistance to imatinib mesylate or have not achieve or lose any cytogenetic response to imatinib mesylate after 12 month of therapy 